Bicocca Open Archive

Logo unimib boa
MAGISTRONI, VERA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.699
EU - Europa 2.311
AS - Asia 899
Continente sconosciuto - Info sul continente non disponibili 10
SA - Sud America 6
AF - Africa 2
OC - Oceania 1
Totale 7.928
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.611
DE - Germania 524
SE - Svezia 385
IE - Irlanda 353
CN - Cina 351
IT - Italia 348
SG - Singapore 328
UA - Ucraina 213
RU - Federazione Russa 161
GB - Regno Unito 131
CA - Canada 87
HK - Hong Kong 72
FI - Finlandia 66
VN - Vietnam 39
IN - India 38
BE - Belgio 34
TR - Turchia 30
FR - Francia 29
DK - Danimarca 27
ID - Indonesia 20
NL - Olanda 16
BG - Bulgaria 9
EU - Europa 9
KR - Corea 8
IR - Iran 6
CZ - Repubblica Ceca 5
BR - Brasile 4
CH - Svizzera 3
JP - Giappone 2
LT - Lituania 2
MU - Mauritius 2
NO - Norvegia 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AR - Argentina 1
AT - Austria 1
AU - Australia 1
MX - Messico 1
MY - Malesia 1
PE - Perù 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
Totale 7.928
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.035
Woodbridge 445
Chandler 354
Dublin 345
Fairfield 332
Houston 264
Frankfurt am Main 249
Singapore 245
Ashburn 237
Jacksonville 224
Wilmington 209
Dearborn 205
Milan 162
Seattle 126
New York 121
Cambridge 107
Santa Clara 96
Göttingen 91
Princeton 91
Shanghai 74
Hong Kong 70
Nanjing 60
Beijing 43
Altamura 41
Lachine 38
Lawrence 35
Brussels 34
Fürstenwalde 32
Boardman 29
Dong Ket 27
Fremont 25
San Diego 25
Shenyang 23
Toronto 23
Helsinki 20
Jakarta 20
Andover 18
Guangzhou 16
Munich 16
Ottawa 16
Tianjin 16
Huizen 14
London 14
Hebei 13
Changsha 12
Jiaxing 12
Nanchang 12
Jinan 10
Kunming 10
Lissone 10
Falls Church 9
Los Angeles 9
Romola 9
Kocaeli 8
Norwalk 8
Plovdiv 8
Pune 8
Nürnberg 7
Verona 7
Auburn Hills 6
Edmonton 6
Hefei 6
Monza 6
Mountain View 6
Buffalo 5
Daejeon 5
Espoo 5
Hangzhou 5
Leawood 5
Washington 5
Chicago 4
Kilburn 4
Mumbai 4
Ningbo 4
Rome 4
San Francisco 4
University Park 4
Zhengzhou 4
Birmingham 3
Bonndorf 3
Dallas 3
Desio 3
Detroit 3
Dottingen 3
Hounslow 3
Kiev 3
Monmouth Junction 3
Moscow 3
Olomouc 3
Alzate Brianza 2
Berlin 2
Bishop 2
Bradford 2
Brno 2
Cedar Crest 2
Central 2
Chengdu 2
Chieti 2
Chongqing 2
Faloppio 2
Totale 5.966
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 406
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 305
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 304
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 289
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 280
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 265
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 245
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 240
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 222
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 222
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 211
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 205
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 204
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 204
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 201
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 189
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 181
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 181
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 181
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 178
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 177
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 175
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 172
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 167
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 166
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition 164
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 163
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 161
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 157
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 153
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 141
Whole-exome sequencing of matched chronic phase and blast crisis CML samples to reveal mechanisms of blast crisis transformation 138
BIM promoter is epigenetically silenced in malignant lymphoid cells, leading to downregulation of BIM expression and protection from apoptosis 137
Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants 135
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 132
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 131
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 131
Mechanisms of Bim epigenetic silencing in anaplastic large cell lymphoma 121
Reactivation of an Epigenetic Silenced Tumor Suppressor Gene BIM in Anaplastic Large Cell Lymphoma Leads to massive Apoptosis 112
Epigenetic changes at the bim locus associated with glucocorticoid resistance in human lymphoid malignancies 110
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents 108
Bim promoter is highly methylated in malignant lymphoid cell lines, leading to downregulation of Bim expression and protection from apoptosis 106
Reversal of glucocorticoid resistance in human lymphoid malignancies with histone deacetylase inhibitors 103
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 102
Role of TMPRSS2/ERG in cellular transformation 94
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 40
Totale 8.209
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.445
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020833 0 0 0 0 0 178 230 86 121 95 96 27
2020/20211.145 62 54 134 119 91 133 105 82 96 115 63 91
2021/2022687 47 67 103 45 47 62 38 32 32 61 47 106
2022/20231.298 157 426 113 127 94 181 15 64 87 5 19 10
2023/2024930 23 32 33 47 126 285 205 15 59 16 4 85
2024/2025724 112 190 108 102 156 56 0 0 0 0 0 0
Totale 8.209